Defence Therapeutics Inc.: Defence Breakthrough: Successfully Engineered Accum-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum-mRNA Cancer Vaccine Program Begins

Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized

Related Keywords

United Kingdom ,Vaccum ,Niedersachsen ,Germany ,Canada ,Vancouver ,British Columbia ,Canadian ,British ,Sebastien Plouffe ,Defence Therapeutics Inc ,Precedence Research ,British Columbia Newsfile Corp ,Defence Therapeutics ,Statement Regarding ,Defence ,Herapeutics ,Breakthrough ,Uccessfully ,Engineered ,Rna ,Vaccine ,Reating ,Platform ,Ivo ,Dancer ,Program ,Egins ,